A vaccine called PEP-CMV for children with certain brain tumors
Original title: PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a mid-stage study, so the vaccine has been given to people before but is still being tested.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests a vaccine in children with high-grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary, DIPG, or medulloblastoma that has come back.
Who this trial is for. This trial is for children with newly diagnosed high-grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary or DIPG. It is also for children whose medulloblastoma has come back. It tests a vaccine called PEP-CMV, which is made to target CMV in tumor cells.
Where it stands. This trial has not reported results. It is asking whether targeting CMV with this vaccine can work as a new way to use the immune system against these tumors. That answer is not in yet.
What this means, and what it doesn't
What it could mean: For now, this is a study, not care a doctor can give you. If your child fits the group being studied, you could ask their care team about it. The team can tell you if it makes sense for your child.
What it doesn't mean: This does not mean the vaccine works. A trial is a test, not a proven treatment. Joining one is not a promise that it will help your child. It is not a promise of a cure. Only the trial team can decide who takes part.
Source: ClinicalTrials.gov, August 24, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.